Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 19/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821453 | 1.00 | HCRTR2 (0.54) | HCRTR2HCRTR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1820754 | 0.90 | HCRTR2 (0.56) | HCRTR2HCRTR1 | |
| SCHEMBL17501822 | 0.90 | HCRTR2 (0.56) | HCRTR2HCRTR1 | |
| SCHEMBL1821513 | 0.89 | HCRTR2 (0.47) | HCRTR2HCRTR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1819747 | 0.87 | HCRTR2 (0.47) | HCRTR2HCRTR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12378866 | 0.87 | HCRTR2 (0.45) | HCRTR2HCRTR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2907898 | 0.85 | HCRTR2 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL17793391 | 0.83 | HCRTR2 (0.55) | HCRTR2HCRTR1 | |
| SCHEMBL19468919 | 0.83 | HCRTR2 (0.55) | HCRTR2HCRTR1 | |
| SCHEMBL19894006 | 0.79 | HCRTR2 (0.47) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049529-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| WO-2008008518-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885NPC1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.